Return to homepagePandemic Pact

Immunogenicity of a Trivalent Vaccine Candidate against Lassa Fever, Ebola, and Marburg virus

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:0 publications

Grant number: 2644873

Grant search

Key facts

  • Disease

    Lassa Haemorrhagic Fever, Ebola, Marburg virus disease

  • Start & end year

    2020
    2024

  • Known Financial Commitments (USD)

    $0

  • Funder

    UK Research and Innovation (UKRI)

  • Research Location

    N/A

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Characterisation of vaccine-induced immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Student is studying the immune response to a trivalent, 'designed' haemorrhagic fever vaccine for Africa. This includes target antigens for Lassa, Ebola and Marburg viruses.